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An LC-MS/MS method was developed and validated to be used as a stability indicating assay for the study of a 3mg/mL
lansoprazole oral suspension. The method utilizes a UPLC (ultra-performance liquid chromatography) column and unique mass
spectrometric detection (ion-trap time-of-ﬂight (IT-TOF)) to achieve a sensitive (LOD 2ng/mL), accurate, and reproducible
quantiﬁcation of lansoprazole. This method reports an intraday and interday coeﬃcient of variation of 2.98 ± 2.17% (n = 5f o r
each concentration for each day) and 3.07 ± 0.89% (n = 20 for each concentration), respectively. Calibration curves (5–25µg/mL)
were found to be linear with an R2 value ranging from 0.9972 to 0.9991 on 4 diﬀerent days. Accuracy of the assay, expressed as %
error, ranged from 0.30 to 5.22%. This method is useful for monitoring the stability of lansoprazole in oral suspension.
1.Introduction
A signiﬁcant problem in pediatric pharmacotherapy is the
lack of commercially available liquid formulations. Proton
pump inhibitors (PPIs) are a class of drugs that are routinely
used in children; however, stability data for extemporaneous
liquid formulations are not readily available for many of
these compounds. In a prospective study performed by Lugo
et al., which included 21 children’s hospitals, an oral suspen-
sion of lansoprazole was the number one reported extem-
poraneous formulation prepared in the inpatient setting [1].
In the study, 19 of 21 hospitals surveyed reported using a
3mg/mL lansoprazole oral suspension; however, there are
limited data regarding the stability of this formulation [1].
Compromised stability, in regard to commercial and extem-
poraneous formulations, is deﬁned as loss of more than 10%
of the active ingredient [2]. While the lack of stability of
lansoprazole in acidic media (such as apple juice) has been
clearly demonstrated [3], the studies examining the stability
inabasicsuspension(preparedin8.4%sodiumbicarbonate)
are conﬂicting. According to a study by DiGiacinto et al.,
the reported stability of lansoprazole suspension was eight
hours at 22◦C and 14days at 4◦C[ 4]. In contrast, a study
performed by Phillips et al. revealed a stability of 4weeks
when lansoprazole was stored in amber plastic vials under
refrigeration and 2weeks at room temperature [5]. Thus,
the commonly accepted stability of lansoprazole suspension
prepared in 8.4%sodium bicarbonate is 14days [6].
Af e wr e p o r t so fl a n s o p r a z o l eq u a n t i ﬁ c a t i o nb yL C - M S /
MS can be found in the literature. Hishinuma et al. [7]
measured lansoprazole and rabeprazole in human serum for
applications in pharmacokinetic studies using a triplequad-
rupole mass spectrometer.Oliveira et al. [8]a n dW ueta l .[ 9]
used similar instrumentation for quantiﬁcation of lansopra-
zole for bioequivalence studies. Other reported quantitative
methods for this drug rely on UV-VIS spectroscopy [10–
12].Theonlypublishedmethodclaimingstability-indicating
properties for lansoprazole utilizes thin-layer chromatogra-
phy and UV-VIS spectroscopy [13].2 International Journal of Analytical Chemistry
The hybrid ion-trap time-of-ﬂight mass spectrometer
conﬁguration is relatively new and was released to the mar-
ket as a competitor for the Orbitrap (Thermo Scientiﬁc,
Waltham, MAss, USA) for applications in proteomics. To
date, this MS conﬁguration has found applications in the
proteomics ﬁeld [14], as well as in metabolomics and
global metabolite proﬁling [15] and lipidomics [16]. One
quantitative method involving the MS conﬁguration has
been published measuring ﬁve lignan standards applicable
to herbal medicines [17]. These investigators noted similar
linearity, precision, accuracy compared to the well-estab-
lished quantitative powers of the triplequadrupole MS con-
ﬁguration; however, the IT-TOF performed at higher sensi-
tivity for all compounds measured [17].
2.MaterialsandMethods
2.1. Equipment and Materials. The lansoprazole and ome-
prazole standards were of USP grade and were purchased
from Spectrum Chemical (Gardena, Calif, USA). The sol-
vents used included methanol, water, and 0.1% v/v formic
acidinacetonitrile.AllofthesesolventswereofLC-MSgrade
(Burdick & Jackson, Morristown, NJ, USA). Lansoprazole
delayed-releasecapsules,USP,of 30mg wereused in thepilot
stability study (TEVA Pharmaceuticals USA, Sellersville, Pa,
USA). The suspension samples were prepared using USP
Grade 8.4%w/v sodium bicarbonate (Hospira, Inc., Lake
Forest, Il, USA). The HPLC column was a Waters Acquity
UPLCBEHC18column,1.7micron,2.1×100mm(Milford,
Ma, USA). The Shimazdu liquid chromatography system
consisted of two LC-20AD pumps with UFLC-XR upgrade,
SIL-20ACHT autosampler, CTO-20A column oven, DGU-
20A3 degasser, and CBM-20A Communications module.
This system was coupled to the Shimazdu IT-TOF mass
spectrometer with an electrospray (ESI) source (Columbia,
Md, USA).
2.2. LC-MS/MS Conditions. All chromatographic separa-
tions were performed using the Waters Acquity UPLC BEH
C18 (1.7 micron, 2.1 × 100mm) column. The isocratic sepa-
ration utilized a mobile phase of 60% water/40% acetonitrile
with 0.1% v/v formic acid at a ﬂow rate of 0.200mL/min.
All injections used a volume of 1µL. All mass spectrometric
measurements were performed using the Shimazdu IT-
TOF with an ESI source operating in positive ion mode.
The detector voltage was set at 1.45kV. Both the source
temperature and CDL were kept at 200◦C. Liquid nitrogen
was used as the nebulizing gas at a ﬂow rate of 1.5L/min.
For quantiﬁcation of lansoprazole and omeprazole, a direct
MS/MS method was used, where the transitions speciﬁc to
the analyte and internal standard were monitored (m/z 370
→ 252andm/z346 → 198forlansoprazoleandomeprazole,
resp.). A 10msec ion acquisition time was used for each MS2
channel.
2.3.LC-MS/MSValidationExperiments. Calibrationandval-
idationstandardswerepreparedin50/50v/vwater/methanol
mixture. The calibration curve consisted of ﬁve points 5,
10, 15, 20, and 25µg/mL lansoprazole. These calibration
standards were prepared using a 100µg/mL stock solution
of lansoprazole in 50/50 water/methanol. Each calibration
and validation solution contained 10µg/mL omeprazole. All
calibration and validation samples were ﬁltered using a 0.22-
micron syringe ﬁlter prior to injection. Quantiﬁcation was
performed using the peak area ratios between lansoprazole
and omeprazole. Five replicates of each of the calibration
points were prepared on each day of validation to assess
precision and accuracy. Precision was calculated as the
relative standard deviation, % RSD = 100 ∗ (SD/mean, SD
standard deviation). To reﬂect the accuracy of the assay, the
% error was calculated as the percent diﬀerence between
the theoretical concentrations and the experimentally deter-
mined concentrations of the replicate samples. The valida-
tion experiments were repeated over a period of 4 days. The
methodlimitofdetection(LOD)wasdeterminedusinga3:1
signal-to-noise criterion.
2.4. Pilot Stability Study Experiment. A lansoprazole sus-
pension (3mg/mL) was prepared by pouring the contents
of ten 30mg capsules of lansoprazole into 100mL of 8.4%
sodium bicarbonate and stirring on a magnetic stir plate
for a minimum of 30minutes. The sample was stored at
room temperature (22◦C) and sampled at the following time
points: 0hr, 8hr, 24hr, 48hr, 72hr, and 168hr. Upon sam-
pling, 0.600mL of suspension was removed by micropipette
and added to 8.4mL of a 50/50 mix of methanol and water
andvortexmixed.Fromthismixture,100µLwasr emo v edb y
micropipette and added to 800µL of the 50/50 solvent mix.
A volume of 100µL of the internal standard stock solution
(100µg/mL), omeprazole, was added to the aforementioned
mixture for a ﬁnal concentration of 10µg/mL omeprazole.
This dilution of lansoprazole used was intended to bring
the ﬁnal sample concentration within the calibration range
(5–25µg/mL). The actual concentration of lansoprazole in
each sample was calculated using the calibration curve
from that day. Before being added to the autosampler vials,
suspensionsampleswereﬁlteredusinga0.22-micronsyringe
ﬁlter.
3. Results and Discussion
3.1.MethodValidation. Themethod wasvalidatedinarange
of 5–25µg/mL. Using a 3:1 signal-to-noise ratio, the limit
of detection (LOD) was determined to be 2ng/mL (0.002ng
on-column). The actual limit of quantiﬁcation (LOQ) is
likely lower than the lowest validation point, as deﬁned by
a10:1signal-to-noiseratio;however,5µg/mLwasthelowest
concentration validated. It is highly likely that the assay
could have been validated in a more sensitive range, but the
objective was to create a method that was easily compatible
with the 3mg/mL starting concentration of the lansoprazole
suspension. Since the suspension is a nonhomogeneous
matrix, the authors felt it best to minimize the number of
dilutions needed for sample preparation as well as maximize
the volume of suspension used for the samples. Working
in the 5–25µg/mL range allowed for this, thus helpingInternational Journal of Analytical Chemistry 3
Table 1: Intraday precision (% relative standard deviation (% RSD)) and accuracy (% error) of the LC-MS/MS assay for quantiﬁcation of
lansoprazole (n = 5 for each concentration for each day).
Concentration of lansoprazole
added (µg/mL)
Concentration of lansoprazole
found (µg/mL) % Relative standard deviation % Error
Day 1
5 5.17 ± 0.15 2.90 2.81
10 10.28 ± 0.12 1.16 2.81
15 15.04 ± 0.65 4.35 0.30
20 20.83 ± 0.27 1.28 4.17
25 24.76 ± 0.72 2.91 0.96
Day 2
5 5.12 ± 0.54 10.54 2.06
10 10.31 ± 0.18 1.79 3.07
15 15.15 ± 0.63 4.13 1.02
20 21.04 ± 0.46 2.18 5.22
25 25.04 ± 0.73 2.90 0.15
Day 3
5 4.95 ± 0.15 3.03 0.81
10 9.90 ± 0.11 1.16 0.98
15 14.48 ± 0.63 4.34 3.47
20 20.04 ± 0.26 1.28 0.21
25 23.82 ± 0.69 2.90 4.74
Day 4
5 5.04 ± 0.15 2.98 0.65
10 10.05 ± 0.12 1.16 0.46
15 14.69 ± 0.64 4.34 2.08
20 20.33 ± 0.26 1.28 1.64
25 24.15 ± 0.70 2.90 3.38
Table 2: Interday precision over four days (% relative standard deviation (% RSD)) and accuracy (% error) of the LC-MS/MS assay for
quantiﬁcation of lansoprazole (n = 20 for each concentration).
Concentration of lansoprazole
added (µg/mL)
Concentration of lansoprazole
found (µg/mL) % Relative standard deviation % Error
5 5.07 + 0.18 3.55 1.18
10 10.13 + 0.20 1.99 1.34
15 14.84 + 0.58 3.93 1.06
20 20.56 + 0.46 2.23 2.81
25 24.44 + 0.89 3.63 2.23
reduce some of the error inherent in sampling from a non-
homogeneous preparation.
Table 1 shows the intraday precision (% RSD) and accu-
racy (% error) for the method (n = 5 for each concentration
for each day). The intraday % RSD ranged from 1.28 to
10.54% and the intraday % error from 0.30 to 5.22%.
Table 2 shows the interday precision over four days (% RSD)
and accuracy (% error) for the method (n = 20 for each
concentration). These data indicate a high reliability and
reproducibility with an interday % RSD ranging from 1.99
to 3.93% and interday % error from 1.06 to 2.81%. These
criteria fall well within what is considered acceptable for
method validation [18].
The use of the Waters Acquity column enabled a separa-
tion that was fast (<3min) and baseline resolved as shown
in Figure 1. The matrix peak shown likely represents the
presence of phthalate contamination, which has been shown
to be ubiquitous in laboratory environments [19]; however,
as shown in Figure 1, it is chromatographically resolved from
the analyte and internal standard peaks. The direct MS/MS
transitions monitored allowed for speciﬁcity in quanti-
ﬁcation of the analyte and internal standard (Figure 2).
3.2. Method Application. To demonstrate that the method
was capable of quantifying lansoprazole in a pharmaceutical
suspension, a one-sample “pilot study” was run using a4 International Journal of Analytical Chemistry
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Figure 1: Sample chromatograms showing (a) solvent blank and (b) suspension sample (0hr).
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Figure 2: LC-MS/MS transitions monitored for the quantiﬁcation of (a) omeprazole and (b) lansoprazole.International Journal of Analytical Chemistry 5
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Figure 3: Graphical representation of the results of the pilot stabil-
ity sample, lansoprazole 3mg/mL suspension stored at room tem-
perature for 7 days.
3mg/mL lansoprazole suspension stored at room temper-
ature. The suspension was sampled periodically and con-
centration of lansoprazole quantiﬁed using the developed
LC-MS/MS method. Suspension samples were spiked with
internal standard (omeprazole) and diluted to fall within
the calibration range as planned for a scaled-up version of
the study. The pilot data, shown in Figure 3, indicate that
stability of lansoprazole in an oral suspension, if stored
at room temperature of 22◦C, would be compromised
after 72hours. Loss of stability was deﬁned as lansoprazole
concentration <90% of the initial concentration at any time
point [2].
4. Conclusions
Themethodpresentedhereistheﬁrstapplicationreportedof
UPLC coupled with the unique IT-TOF mass spectrometric
detector to quantify this drug. The use of UPLC is becoming
widely accepted as a means to achieve higher-resolution
separations compared to conventional HPLC, ultimately
resulting in higher sensitivity and fast run times [20]. Fur-
thermore, the use of the IT-TOF mass spectrometer provides
the potential for accurate mass data collection on degrada-
tion products, something that is not readily achieved using
moreconventionaltriplequadrupoleinstruments.Whilethis
method oﬀers a comparable option to existing LC-MS assays
for quantiﬁcation of lansoprazole in terms of accuracy and
precision,itstandsasoneofthefewquantitativeapplications
of the hybrid IT-TOF mass analyzer conﬁguration as well
as one of two stability-indicating methods for this drug.
Ultimately, this method can be applied to monitor the
stability of lansoprazole in oral suspensions with conﬁdence
of accuracy, precision, and speciﬁcity.
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